NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

Michel M. van den Heuvel; Marcel Verheij; Rogier Boshuizen; Jose Belderbos; Anne-Marie C. Dingemans; Dirk De Ruysscher; Julien Laurent; Robert Tighe; John Haanen; Sonia Quaratino

doi:10.1186/s12967-015-0397-0

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

Michel M. van den Heuvel, Marcel Verheij, Rogier Boshuizen, Jose Belderbos, Anne-Marie C. Dingemans, Dirk De Ruysscher, Julien Laurent, Robert Tighe, John Haanen, Sonia Quaratino

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	32
Journal	Journal of Translational Medicine
Volume	13
DOIs	https://doi.org/10.1186/s12967-015-0397-0
Publication status	Published - 27 Jan 2015

Keywords

Lung cancer
NHS-IL2
Immunotherapy
Radiotherapy
Phase Ib

Access to Document

10.1186/s12967-015-0397-0

Cite this

van den Heuvel, M. M., Verheij, M., Boshuizen, R., Belderbos, J., Dingemans, A-M. C., De Ruysscher, D., Laurent, J., Tighe, R., Haanen, J., & Quaratino, S. (2015). NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. Journal of Translational Medicine, 13, [32]. https://doi.org/10.1186/s12967-015-0397-0

van den Heuvel, Michel M. ; Verheij, Marcel ; Boshuizen, Rogier ; Belderbos, Jose ; Dingemans, Anne-Marie C. ; De Ruysscher, Dirk ; Laurent, Julien ; Tighe, Robert ; Haanen, John ; Quaratino, Sonia. / NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. In: Journal of Translational Medicine. 2015 ; Vol. 13.

@article{2d4d67ee9ede485f8f3c7b8269ea8900,

title = "NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy",

keywords = "Lung cancer, NHS-IL2, Immunotherapy, Radiotherapy, Phase Ib",

author = "{van den Heuvel}, {Michel M.} and Marcel Verheij and Rogier Boshuizen and Jose Belderbos and Dingemans, {Anne-Marie C.} and {De Ruysscher}, Dirk and Julien Laurent and Robert Tighe and John Haanen and Sonia Quaratino",

year = "2015",

month = jan,

day = "27",

doi = "10.1186/s12967-015-0397-0",

language = "English",

volume = "13",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central Ltd",

}

van den Heuvel, MM, Verheij, M, Boshuizen, R, Belderbos, J, Dingemans, A-MC , De Ruysscher, D, Laurent, J, Tighe, R, Haanen, J & Quaratino, S 2015, 'NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy', Journal of Translational Medicine, vol. 13, 32. https://doi.org/10.1186/s12967-015-0397-0

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. / van den Heuvel, Michel M.; Verheij, Marcel; Boshuizen, Rogier; Belderbos, Jose; Dingemans, Anne-Marie C.; De Ruysscher, Dirk; Laurent, Julien; Tighe, Robert; Haanen, John; Quaratino, Sonia.

In: Journal of Translational Medicine, Vol. 13, 32, 27.01.2015.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

AU - van den Heuvel, Michel M.

AU - Verheij, Marcel

AU - Boshuizen, Rogier

AU - Belderbos, Jose

AU - Dingemans, Anne-Marie C.

AU - De Ruysscher, Dirk

AU - Laurent, Julien

AU - Tighe, Robert

AU - Haanen, John

AU - Quaratino, Sonia

PY - 2015/1/27

Y1 - 2015/1/27

KW - Lung cancer

KW - NHS-IL2

KW - Immunotherapy

KW - Radiotherapy

KW - Phase Ib

U2 - 10.1186/s12967-015-0397-0

DO - 10.1186/s12967-015-0397-0

M3 - Article

C2 - 25622640

VL - 13

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 32

ER -